Innovative MedTech Rebrands as AnTix Holdings in Strategic Shift to Entertainment Technology

Innovative MedTech, Inc. has completed its corporate rebranding and name change to AnTix Holdings, Inc., marking a significant strategic shift from medical technology to the online ticketing and entertainment technology sector. The company, which will continue trading under the OTC ticker symbol IMTH for now, filed a Certificate of Amendment with the State of Delaware on September 19, 2025, to formalize the name change from Innovative MedTech, Inc. to AnTix Holdings, Inc.

Michael J. Friedman, President and CEO of AnTix Holdings, described the rebranding as an exciting milestone that aligns with the company's new strategic direction. Through this transition, the company is expanding into the growing online ticketing market where it plans to apply artificial intelligence and Web 3.0 tools to improve the ticketing and live experience for consumers and partners. Friedman noted that the company's ticketing technology has already begun generating revenues, providing what he believes will be a strong foundation for future growth.

The strategic pivot represents a fundamental change in the company's business model and market focus. Friedman emphasized the company's goal to build value through innovation, execution and acquisition in a market that he described as ripe for significant technological change. The company remains focused on strengthening its position and appeal to a broad base of investors while increasing shareholder value. Additional information about the company's plans is expected to be shared in the near future.

While the corporate name has changed, outstanding stock certificates for shares of the company remain valid and do not need to be exchanged at this time. The company intends to file with FINRA to effectuate both the name change and a change to its ticker symbol from IMTH to a new symbol. For more information about the company's new direction and technology offerings, visit https://www.antixholdings.com.

The company's transformation comes as it maintains its exclusive licensing agreement for the Oral Thrush application of Shear Kershman Labs' BioViscid™ bio-adhesive encapsulation, though the primary focus has clearly shifted to the entertainment technology sector. This strategic move positions AnTix Holdings to compete in the rapidly evolving ticketing industry where technological innovation is increasingly driving market differentiation and customer experience.